Description: Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Home Page: www.nanobiotix.com
60 rue de Wattignies
Paris,
75012
France
Phone:
33 1 40 26 04 70
Officers
| Name | Title |
|---|---|
| Mr. Laurent Levy Ph.D. | Co-Founder, Pres of the Exec. Board & CEO |
| Mr. Bart Van Rhijn | CFO & Member of Exec. Board |
| Ms. Anne-Juliette Hermant M.A. | Chief People Officer & Member of Exec. Board |
| Prof. Para Prasad Ph.D. | Co-Founder and Member of Scientific Board |
| Mr. Earl J. Bergey Ph.d. | Co-Founder |
| Mr. Alain Dostie | Chief Operating Officer |
| Ms. Kathryn M. McNeil | Sr. VP of Investor Relations |
| Mr. Brandon Owens | VP of Strategic Marketing & Corp. Communication |
| Ms. Elsa Borghi | Head of Innovation & Drug Discovery |
| Ms. Sarah Gaubert | Head of Communication & Public Affairs Department |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 71.885 |
| Price-to-Sales TTM: | 49.8378 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 103 |